CD8A and melanoma: Inducing lymph angiogenesis with a vaccine overexpressing VEGF-C (“VEGFC vax”) resulted in increased infiltration of CD8α+ cross-presenting DCs and CD8+ T cells and hence better tumor control in combination with anti-PD-1 in a B16 melanoma mouse model [35].